With its unique mechanism of action, Semaglutide has shown promising results in helping individuals achieve sustainable weight loss
In 2014, OPM issued Carrier Letter 2014-04 clarifying that it is not permissible for FEHB plans to exclude weight loss drugs from FEHB coverage on the basis that obesity is a lifestyle condition and not a medical one or that obesity treatment is cosmetic. In 2019, OPM reminded carriers of their obligation to cover intensive behavioral therapy (IBT) for obesity management if referred as the result of a preventive screening
Therefore, compared to other GLP-1R agonists, exendin-phe1 possesses advantageous pharmacological properties that maximizes insulin secretion
If the Schedule 3 factors are not applicable, then the medicine is assessed against the Schedule 2 factors
Cycling Practical application: Cycling involves scheduled treatment breaks to lower tolerance and keep it effective
Key takeaways Mounjaro (tirzepatide) and Ozempic (semaglutide) are similar GLP-1 medications that are FDA-approved to treat type 2 diabetes